placeholder newsslider

News in Detail

New Technologies for Outcome Measures in Uveal Melanoma

Basel Series of Special Interest Focus Groups (SIFG) - „New Technologies for Outcome Measures in Uveal Melanoma”

In Collaboration with the European Ocular Oncology Group and the International Society of Ocular Oncology


Date June 8th – 9th, 2020
Organizer European Vision Institute EEIG
Venue: Institute of Molecular and Clinical Ophthalmology Basel (IOB),
University of Basel, Mittlere Strasse 91, 4056 Basel, Switzerland



Day 1 - June 8th, 2020

15:00 Welcome and Introduction
(M. Jager & H. Scholl)
15:00 – 15:40 Cancer predisposition syndrome - detection of germline BAP1 in patients with UM, and detection of other tumors
T. Kivela, University of Helsinki, FI & C. Chau, LUMC, Leiden, NL
15:40 – 16:20 Deciding on the diagnosis of an iris nevus vs melanoma
V. Cohen, Moorfields Eye Hospital, London, UK & C. Brouwer, LUMC, Leiden, NL
16:20 – 16:40 Coffee Break
16:40 – 17:20 Deciding on the diagnosis of a choroidal nevus vs Melanoma using OCT or Oxymap
B. Romanowska-Dixon, Jagellonian University Krakow, PL & N. Brouwer,LUMC, Leiden, NL
17:20 – 18:00 Quantitative Mreye for diagnosis, treatment planning and follow-up of UM
J.W. Beenakker, LUMC, Leiden, NL
18:00 – 18:40 MOLES, a new algorithm to distinguish benign naevi from malignant melanomas; using databases
B. Damato, Oxford, UK
19:30 Dinner (Board Members and invited Speakers)
Restaurant Teufelhof, Basel (walking distance)

Day 2 - June 9th, 2020

08:30 – 09:10 Success rate of prognostic biopsies and test for prognostication (BAP1 staining vs chromosomes vs AJCC)
S. Coupland, Liverpool, UK & J. Kiilgaard, Copenhagen, DK
09:10 – 09:50 Ocular conservation, techniques to prediction vision and complications, predicting glaucoma
Miltiadis Fiorentzis, Essen, DE & L. Zografos, Lausanne, CH
09:50 – 10:30 Complications after endoresection, proper localization of plaques
Aline Riechardt, Berlin, DE & G. Willerding, Berlin, DE
10:30 – 11:00 Coffee Break
11:00 – 11:40 Response rates and complications for the different treatments for metastic disease in UM
S. Piperno-Neumann, Paris, FR
11:40 – 12:20 Predicting metastatic death, and quality of life
T. Kivela, Helsinki, FI & B. Damato, Oxford, UK
12:20-12:30 Summary and Farewell
(M. Jager & H. Scholl)